European pharmaceutical bosses have called on the EU to increase drug prices towards the much higher levels paid by the US, ...

Eli Lilly and Company is leading a global effort to protect wildlife by shifting away from horseshoe crab blood and using a ...

Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

A recent medical trial could help deliver the first daily weight loss pill capable of cutting down obesity as effectively as ...

The most recent trading session ended with Eli Lilly (LLY) standing at $827.54, reflecting a +1.16% shift from the previouse trading day's closing. The stock lagged the S&P 500's daily gain of 2.51%.

Texas health officials said Tuesday reported measles cases have now surpassed 600 with most of it affecting children and ...

The health-care industry group of the S&P 500 has fought back to near the flat line for the year to date. Orchestra BioMed Holdings shares initially surged after the maker of medical devices said a ...

UnitedHealth's new security spending disclosures underscore how a fatal shooting in December caused companies to reassess the ...

Two years ago, the Pharmaceutical Research and Manufacturers of America (PhRMA) trade group faced a mini-exodus as several ...

Roche will invest $50 billion in U.S. manufacturing, including a new plant in Indiana. The Trump administration is ...

Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.